LENVATINIB for Differentiated Thyroid Cancer

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Differentiated Thyroid Cancer+1 MoreLENVATINIB - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is being done to see if lenvatinib is safe and effective in treating patients with a type of thyroid cancer called differentiated thyroid cancer (DTC) that has spread outside of the thyroid gland.

Eligible Conditions
  • Differentiated Thyroid Cancer
  • Advanced Cancer

Treatment Effectiveness

Study Objectives

1 Primary · 6 Secondary · Reporting Duration: Up to 18 months

112 Days
Change in Surgical complexity and morbidity score (SCMS)
Overall R0/R1 resection rate
Primary surgery response rate
Resection rate of R0
Resection rate of R1
Unresectable to resectable conversion rate
Up to 18 months
Therapeutic procedure

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Side Effects for

Treatment (Lenvatinib)
100%Fatigue
100%Anorexia
100%Proteinuria
67%Dry skin
67%Nausea
67%Hypertension
67%Diarrhea
67%Hyperthyroidism
33%Palmar-plantar erythrodysesthesia syndrm
33%Gastrointestinal disorders - Oth spec
33%Vomiting
33%Arthralgia
33%Constipation
33%Musculoskeletal, conn tissue - Oth spec
33%Aspartate aminotransferase increased
33%Gastroesophageal reflux disease
33%Lymphocyte count decreased
33%Mucositis oral
33%Hypothyroidism
33%Weight loss
33%Anxiety
This histogram enumerates side effects from a completed 2022 Phase 2 trial (NCT03008369) in the Treatment (Lenvatinib) ARM group. Side effects include: Fatigue with 100%, Anorexia with 100%, Proteinuria with 100%, Dry skin with 67%, Nausea with 67%.

Trial Design

1 Treatment Group

LENVATINIB
1 of 1

Experimental Treatment

30 Total Participants · 1 Treatment Group

Primary Treatment: LENVATINIB · No Placebo Group · Phase 2

LENVATINIB
Drug
Experimental Group · 1 Intervention: LENVATINIB · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 18 months

Who is running the clinical trial?

Eisai Inc.Industry Sponsor
506 Previous Clinical Trials
145,029 Total Patients Enrolled
Massachusetts Eye and Ear InfirmaryLead Sponsor
99 Previous Clinical Trials
12,194 Total Patients Enrolled
Gregory Randolph, MDPrincipal InvestigatorMassachusetts Eye and Ear Infirmary (MEEI)

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you: